analytical and biologic variability of these factors, and there has been little published about using analytical and biologic variability in the interpretation of CVD models.
In epidemiologic studies, intraindividual and analytical variance (a, 2 and a A 2 ) diminish measures of correlation and risk, may alter our perception of the physiologic relevance of a variable, and generally underestimate a univariate measure of association (3) . In case of multivariate models, however, the observed effects of these variables may be either under-or overestimated, if even only one variable is measured imprecisely (4) (5) (6) . Although methods exist to adjust relative risks using multivariate relative risk techniques, these methods may require assumptions which are not met by the data. Some investigators advocate focusing on the interpretation of the observed effect or designing studies to prevent measurement imprecision rather than adjusting for variation in the analyses imprecisely (4) . There is no consensus on how variability measures should be used in epidemiologic studies.
A proportionately large population variance (a G 2 ) as part of the total variation (a T 2 ; G T 2 = a G 2 + a, 2 (intraindividual variation) + O A 2 (analytical variation)) enhances a factor's reliability, and generates a more accurate estimate of the variable-disease association (7) . In addition, an increased o G 2 may also improve the ability of multivariate models to detect correlations among variables, whereas an increased a, 2 may increase the probability of measuring an extreme value for an individual. This implies that some factors may be better suited to epidemiologic study design by nature of their biologic and analytical variability than others.
The role of variability in hemostatic risk factors of CVD was initially reported by Thompson et al. (8) . More recently, others have contributed to addressing the implications of biologic and analytical variability on sample size calculations (9, 10), short-term factor reliability (11, 12) , and the effects of selected patient and sample characteristics (9, 11, 12) on factor biovariability. We present long-term variability data on 12 hemostasis, fibrinolysis, and inflammation factors (plus cholesterol for comparison). For six of these risk factors, no variability data exists in the literature. We suggest that these data may be used to: 1) adjust continuous measures of association between factors in univariate analyses; 2) evaluate variables for use in epidemiologic studies based on their characteristic variation; and 3) estimate the likelihood of observing relations between CVD and these factors compared with cholesterol, assuming equivalent physiologic relevance.
MATERIALS AND METHODS

Population
We recruited 26 apparently healthy individuals (16 women and 10 men) who ranged in age from 23 to 72 years. Four of the women were postmenopausal. Subjects provided information regarding recent medication use and state of general health. Subjects were asked to abstain from caffeine intake prior to sample collection. Early morning venous blood samples were collected following overnight fast at 3-week intervals over 24 weeks, and samples were analyzed all at one time.
Blood collection and analysis
One citrate tube (0.129 mol/liter of citrate/citric acid; Becton Dickinson, San Jose, California) and one SCAT-1 tube (200 KlU/ml Aprotinin, 50 |xM PPACK (d-phenylalanyl-prolyl-arginyl-chloromethyl ketone) 4.5 mM EDTA, Haematological Technologies, Essex Junction, Vermont) were obtained following venipuncture. To minimize plasminogen activator inhibitor-1 (PAI-1) release during activation of platelets, blood collection and handling recommendations were followed as previously described (13) . PAI-1 antigen was measured using enzyme-linked immunosorbent assay (ELISA) (14) . PAI-1 activity was assayed using the American Diagnostica (Greenwich, Connecticut) plasmin substrate, Spectrolyse-PL, to measure PAI-1 inhibition of t-PA activation of plasminogen to plasmin in the presence of a fibrin catalyst (15) . The assay was performed according to manufacturer's instructions with the exceptions that plasminogen and fibrin catalyst were produced in our laboratory. Plasminogen isolation was performed by affinity chromatography on lysinesepharose followed by gel filtration using ACA-44. The fibrin catalyst was made by cyanogen bromide digestion of fibrinogen purified from plasminogen/ plasmin depleted plasma.
Tissue-plasminogen activator (t-PA) antigen (16) and t-PA/PAI-1 complex (17) were measured with ELISA. Plasmin-alpha-2-antiplasmin complex (PAP) was measured by ELISA developed by Holvoet et al. (18) . The fibrin fragment D-dimer was measured by ELISA (19) . Monoclonal antibodies for the PAI-1 antigen, t-PA antigen, and the t-PA/PAI-1 complex assays were generous gifts of Dr. Desire Collen at the Center for Molecular and Vascular Biology at the University of Leuven, Belgium.
Prothrombin fragment Fl-2 (Fl-2) was measured with ELISA (Baxter-Dade, Miami, Florida) (20) . Fibrinopeptide A (FPA) was measured on bentoniteextracted, fibrinogen-free plasma by a double antibody competition radioimmunoassay (BykSangtec Diagnostica) (21) .
C-reactive protein (CRP) was determined by ELISA (antibodies and antigens from Calbiochem, LaJolla, California) (22) . Fibrinogen was measured with the ST4 instrument (Diagnostica Stago) and bovine thrombin (Parke-Davis, Lititz, Pennsylvania) by the general method of Clauss (23) .
Factor XIa-alpha-1-antitrypsin (FXIa-alAT) was measured by ELISA with antigens and antibodies from Affinity Biologicals, Inc., Hamilton, Ontario. Thrombin antithrombin complex (TAT) was determined by enzyme immunoassay (Behring Diagnostics, Inc., Westwood, Massachusetts).
Cholesterol was measured by a Centers for Disease Control and Prevention-certified enzymatic method, as described previously (24, 25) .
Statistical analysis
Random effects nested analysis of variance (ANOVA) was performed to separate the sources of variation (26, 27 ), defined as s A 2 = average variance of replicate assays (within-run analytical variance), s 2 = average biologic within-subject variance, and s c 2 = variance of true means among subjects. The coefficient
Variability in Hemostasis, Fibrinotysis, and Inflammation 263 of variation (CV) is defined as 100 percent x (standard deviation/mean), and was calculated for each component of variance (CV A , CV,, and CV G ). We used the standard constant variance model, which assumes that at differing analyte concentration, intraindividual and analytical variation remain constant {27).
We calculated the ratio CV/CV G = I,, referred to as the Index of Individuality, which is a measure of how individuals vary relative to the population distribution. The proportion of total variance attributable to interindividual variation (reliability factor) was also
to the proportion of variance attributable to withinperson and analytical variation in a similar fashion.
Outlier removal was based on the Cochran test, using both the ratio of the maximum variance to the sum of the variances, and the variances of the specimen means among the individual subjects (28), as suggested by Fraser and Harris (26) . In general, the medical history provided by the volunteers did not contribute to the explanation of outlying values. However, in the case of CRP, all three outlying values were obtained from individuals who reported influenza symptoms.
Pearson correlation coefficients were adjusted by the method of Liu et al (29) . The actual correlation estimated was defined as r c = r g (1 -r (1 + (s 2 /ks G 2 ))) m , where r o = the observed correlation between factor X and a random variable Z, r. = the actual correlation between the true mean of factor X and a random variable Z (corrected for attenuation), sf = sample intraindividual variation, s c 2 = sample between individual variation, and k = the number of measurements for each individual.
The validity coefficient p Ti , an estimate of how much the observed measure differs from the true measure due to its variability, was defined as (1 -r (1 + (s 2 /ks c 2 ))y n , where k = the number of measurements for each individual (29) . The minimum number of measurements for each individual to achieve a validity coefficient of 0.91 (validity coefficient of cholesterol) was derived as k = (0.91 2 /(l -0. 91 2 ) x (sf/s/)) (29) . The calculation assumes that the analytical variation is very small compared with intraindividual variation.
SPSS for Windows was used for descriptive analyses (30). A Lotus spreadsheet template was developed and used for the nested ANOVA calculations.
RESULTS
The median age of the population was 37 years. One of the women became pregnant during the study, and was removed from the analyses. Three participants were smokers.
Descriptive statistics are shown in table 1. Among the hemostatic factors, PAP, PAI-1 ag, and fibrinogen had the lowest analytical variation, approaching that of cholesterol. Although cholesterol had the lowest analytical imprecision among the 13 variables, all of the variables had an "acceptable" degree of analytical pre- •SD, standard deviation; CV, coefficient of variation; ANOVA, analysis of variance; CV A , analytical coefficient of variation; CV,, intraindividual coefficient of variation; CV 0 , individual coefficient of variation; t-PA, tissueplasminogen activator; ag, antigen; PAI-1, plasminogen activator-1; tPA/PAl, tissue plasminogen activator/plasminogen activator inhibitor-1 complex; PAP, plasmin-alpha-2-antiplasmin complex; F1-2, prothrombin fragment F1-2; TAT, thrombin-antithrombin complex; FPA, fibrinopeptide A; FXIa-a1AT, factor Xlaalpha-1-antitrypsin; CRP, C-reactive protein.
t CV calculated from repetitive use of control materials during the anaiyses of the samples in this study. t CV calculated from samples measured in a separate, but contemporaneous study. § CV calculated from monthly mean values measured over one year.
cision (CV A < 1/2 CV,) (26) . The CV determined from control materials were not consistently smaller or larger than the calculated CV A .
The relative variance components of each variable are presented in table 2 as the Index of Individuality (Ij) and the proportion of variation due to the berweenperson (R), intraindividual, and analytical components.
Comparison R values from variability studies in middle-aged persons are given in parentheses (9, 11, 12) . The Ij, a measure of how individuals vary related to the population distribution, ranged from 0.1 to 1.8, with 11 of 12 measures at 0.9 or less. Therefore, despite greater CV, and CV A , many of these variables have I,'s similar to cholesterol (I, = 0.44). Within groups of fibrinolysis, inflammation, and hemostasis markers, there was a gradation of the individuality indexes and reliability factors. The R was essentially a mirror image of the ŝ cale, reflecting the small addition of the analytical variation to the total variation.
In general, the intraindividual variation component increased for each analyte over the seven timepoints (table 3) , whereas the analytical component of variation was essentially unchanged (data not shown). Examination of the standardized CV, (obtained by dividing the subsequent CV, for each analyte by the initial CV, for each analyte) showed that the mean CV, across all 13 hemostatic factors at 6 and 9 weeks were lower than the mean CV, at 24 weeks (paired Mest, p < 0.05); however, there was no difference at >12 weeks (data not shown). Observed validity coefficients and the number of replicate specimens needed to achieve the validity coefficient level of cholesterol (0.91) are shown in table 4. In general, only one or two measurements were necessary to reduce the intraindividual variation of the factor to {hat of cholesterol. The three factors which required more than three measurements were FPA, Fl-2, and fibrinogen, all procoagulant assays. Table 5 shows adjusted Pearson correlation coefficients for the hemostatic factors based on a hypothetical and arbitrary "observed" correlation of 0.3000. The percent change ranged from 1.0 to 104 percent (cholesterol: 11.1 percent), and only three factors (all procoagulant) reported a percent change over 30 percent.
DISCUSSION
The major findings of this study are: 1) overall, most of the examined hemostatic and inflammatory factors have analytical and intraindividual variation similar to cholesterol, implying that if pathophysiologic relations between these factors and CVD exist on the same magnitude as they do for cholesterol, the relations should be statistically apparent; 2) accurate assessment of the intraindividual component of variation for some assays may require long-term evaluation (>12 weeks); and 3) within the groups of inflammation, fibrinolysis, and hemostasis, some factors appeared better suited to epidemiologic study than others, which may help in selecting factors for analyses, or interpreting results which include these factors.
Previous studies have compared the biovariability of factors relative to each other (8, 11) , and have sug- gested an arbitrary limit of acceptable analytical and intraindividual variation (9) . We chose to compare the biovariability data of our hemostatic factors with cholesterol because it is a well-established CVD risk factor. Our results suggest that while there is a range, most of the examined thrombotic factors have a similar statistical power to detect physiologic relations as cholesterol, at least in bivariate correlations. For several factors, our variability results are similar to those reported in a short-term variability study in middle-aged persons (11, 12) and in persons with underlying CVD (9) . In this long-term study, FPA and fibrinogen had higher and lower reliability, respectively. Comparison of the analytical variability data for the FPA assay indicates the increase in the reliability factor in our study may be due to less assay variability, whereas the decrease in the reliability factor of the fibrinogen assay may be due to increased intraindividual variation. Because of the variability associated with processing each sample (split samples were used for the duplicates), and batch-to-batch changes were not estimated in this study, our analytical variability should be considered a minimum for our assay methods.
In several cases, the intraindividual coefficient of variation increased over the first 12 weeks of examination, which suggests that accurate assessment of the intraindividual component of variation may require extended observation. The Atherosclerosis Risk in Communities (ARIC) group (11) has reported that age, sex, and variable level do not significantly influence intraindividual variation, and de Maat et al. (9) showed that the intraindividual variability of fibrinogen was not increased in patients with underlying disease com-pared with healthy controls, nor influenced by a polymorphism in the fibrinogen gene. However, it is possible that unexplored genetic polymorphisms may contribute to the length of time a variable must be studied to accurately assess intraindividual variation.
The gradation of factors within subgroups of hemostatic factors implies that some are better suited to epidemiologic study than others. The methods that we used to evaluate variables in this study are driven by the relative intraindividual variation and interindividual variation, and do not reflect the analytical variation directly. In fact, the variables with the lowest analytical variation in the procoagulant and inflammation groups (PAP, fibrinogen, and CRP) were not the variables with the best index of individuality, or factors which required the fewest replicate specimens (t-PA, TAT, and FXIaal AT). The selection of variables will also be tempered by the pathophysiology of the epidemiologic questions.
Although the methods introduced to correct for variation in bivariate statistics do not apply to multivariate models (4-6), they may still be useful in interpretation or in cautioning interpretation of multivariate models. Statistics from bivariate correlations may be used in deciding what factors to include in building multivariate models. Our results indicate that an observed correlation coefficient may be diminished by as much as one-half of its actual value by failing to account for intraindividual and analytical variation. This may lead to underestimating the strength of the true correlation between two variables.
The major weaknesses of this study are a limited number of subjects, reducing the ability to stratify on factors such as disease and smoking to assess their role in factor variation and stability. The strengths are a repeated measures study design, covering an extended period of time, with appropriate blood collection and storage procedures. We also examined a large number of thrombosis risk factors within different major subgroups of coagulation, fibrinolysis, and inflammatory factors, some of which have never been examined before, and others which have not been examined over a long time period.
